EGFR and heart failure: reported a 67-year-old woman treated with first-generation EGFR TKI erlotinib and then changed the osimertinib without resistance; 7 months after osimertinib initiation, she presented with shortness of breath and was diagnosed with heart failure and had to use erlotinib again.